CytoDyn Inc. Announces Major Extension of Convertible Note Maturities and Revised Payment Terms

Key Points:

• CytoDyn Inc. has extended the maturity dates on two significant secured convertible promissory notes, each originally issued for \$28.5 million.
• The maturity dates for Note 1 and Note 2 have been extended by 36 months, now due April 5, 2029 and April 23, 2029, respectively.
• As part of the extension, CytoDyn will make monthly payments to the noteholders in the form of common stock, totaling \$1,000,000 per month for both notes combined.
• The payment calculation is based on the lower of (i) the previous trading day’s closing price or (ii) the average of the previous five trading days’ closing prices.
• The annual interest rate on each note has been reduced to 5%, which could lower the company’s future interest expense.

Details and Analysis for Investors:

• This extension is a material definitive agreement that fundamentally changes CytoDyn’s near-term financial obligations and cash flow profile.
• By extending the maturity dates by three years, CytoDyn has alleviated the risk of a large debt repayment in 2026, which could have pressured liquidity or triggered a need for refinancing or asset sales.
• The monthly payments in stock (rather than cash) will reduce immediate cash outflows, but will increase the company’s share count and may result in dilution for existing shareholders.
• The payment formula, which uses the lower price between the previous day or five-day average, means the company will issue more shares if the stock price declines, further increasing dilution risk in a weak market environment.
• The reduction of the interest rate to 5% from prior terms (not specified in the filing, but typically higher for such notes) will reduce the company’s future interest expense, potentially improving net income and cash flows.
• There is no indication of any trading symbol or exchange registration for CytoDyn shares at this time, which may affect liquidity and visibility for investors.
• CytoDyn is not classified as an emerging growth company, and has not elected to use extended transition periods for new or revised financial accounting standards.

Shareholder Considerations:

• The extension of note maturities and switch to stock-based payments are both potentially price-sensitive actions. They signal improved short-term liquidity but raise the risk of dilution, which could negatively impact share prices if not offset by positive operational developments.
• Investors should monitor CytoDyn’s ability to manage dilution and communicate effectively with the market about its plans for growth and capital structure.
• The company’s decision to lower interest rates may be viewed favorably, but only if the underlying business can deliver improved results or offset the dilution effects.

Signatures:
The filing was signed by Robert E. Hoffman, Chief Financial Officer of CytoDyn Inc., on March 24, 2026.

Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research and consult with professional advisors before making investment decisions. CytoDyn Inc.’s actions described herein may have significant implications for share price, but all investments carry risk.

View CytoDyn Inc. Historical chart here